研究单位：[1]Peking University Cancer Hospital & Institute[2]Nanjing Leads Biolabs Co.,Ltd[3]Anhui Provincial Hospital,Hefei,Anhui,China,230002[4]The Second Hospital of Anhui Medical University,Hefei,Anhui,China,230601[5]Peking Union Medical College Hospital,Beijing,Beijing,China,100005[6]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[7]Beijing Cancer Hospital,Beijing,Beijing,China,100142[8]Chongqing Cancer Hospital,Chongqing,Chongqing,China,400030[9]The First Affiliated Hospital,Sun Yat-sen University,Guangzhou,Guangdong,China,510062[10]Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050011[11]Affiliated Hospital of Hebei University,Shijiazhuang,Hebei,China,050031[12]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[13]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[14]Hubei Cancer Hospital,Wuhan,Hubei,China,430079[15]Hunan Cancer Hospital,Changsha,Hunan,China,410031[16]Nanjing Drum Tower Hospital,Nanjing,Jiangsu,China,210008[17]The Ferst Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330006[18]Fudan University Shanghai Cancer Center,Shanghai,Shanghai,China,200032[19]The First Affiliated Hospital of Xi'An Jiaotong University,Xi''an,Shanxi,China,710061[20]Sichuan Cancer Hospital & Institute,Chengdu,Sichuan,China,610042[21]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China,300181[22]The First Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003[23]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310005[24]Cancer Hospital of The University of Chinese Academy of Sciences,Hangzhou,Zhejiang,China,310022[25]The 1"Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,China,325015
研究目的：
To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors
